Abstract
Objective: Present a new model-based tight glycaemic control approach using variable insulin and nutrition administration. Background: Hyperglycaemia is prevalent in critical care. Current published protocols use insulin alone to reduce blood glucose levels, require significant added clinical effort, and provide highly variable results. None directly address both the practical clinical difficulties and significant patient variation seen in general critical care, while also providing tight control. Methods: The approach presented manages both nutritional inputs and exogenous insulin infusions using tables simplified from a modelbased, computerised protocol. Unique delivery aspects include bolus insulin delivery for safety and variable enteral nutrition rates. Unique development aspects include the use of simulated virtual patient trials created from retrospective data. The model, protocol development, and first 50 clinical case results are presented. Results: High qualitative correlation to within +/-10% between simulated virtual trials and published clinical results validates the overall approach. Pilot tests covering 7358 patient hours produced an average glucose of 5.9 +/- 1.1 mmol/L. Time in the 4-6.1 mmol/L band was 59%, with 84% in 4.0-7.0 mmol/L, and 92% in 4.0-7.75 mmol/L. The average feed rate was 63% of patient specific goal feed and the average insulin dose was 2.6U/hour. There was one hypoglycaemic measurement of 2.1 mmol/L. No departures from protocol or clinical interventions were required at any time. Summary: Modulating both low dose insulin boluses and nutrition input rates challenges the current practice of using only insulin in larger doses to reduce hyperglycaemic levels. Clinical results show very tight control in safe glycaemic bands. The approach could be readily adopted in any typical ICU.
Keywords: hyperglycaemia, SPRINT Protocol, APACHE II score, Virtual Trial, blood glucose
Current Drug Delivery
Title: Model-Based Insulin and Nutrition Administration for Tight Glycaemic Control in Critical Care
Volume: 4 Issue: 4
Author(s): J. Geoffrey Chase, Geoffrey M. Shaw, Thomas Lotz, Aaron LeCompte, Jason Wong, Jessica Lin, Timothy Lonergan, Michael Willacy and Christopher E. Hann
Affiliation:
Keywords: hyperglycaemia, SPRINT Protocol, APACHE II score, Virtual Trial, blood glucose
Abstract: Objective: Present a new model-based tight glycaemic control approach using variable insulin and nutrition administration. Background: Hyperglycaemia is prevalent in critical care. Current published protocols use insulin alone to reduce blood glucose levels, require significant added clinical effort, and provide highly variable results. None directly address both the practical clinical difficulties and significant patient variation seen in general critical care, while also providing tight control. Methods: The approach presented manages both nutritional inputs and exogenous insulin infusions using tables simplified from a modelbased, computerised protocol. Unique delivery aspects include bolus insulin delivery for safety and variable enteral nutrition rates. Unique development aspects include the use of simulated virtual patient trials created from retrospective data. The model, protocol development, and first 50 clinical case results are presented. Results: High qualitative correlation to within +/-10% between simulated virtual trials and published clinical results validates the overall approach. Pilot tests covering 7358 patient hours produced an average glucose of 5.9 +/- 1.1 mmol/L. Time in the 4-6.1 mmol/L band was 59%, with 84% in 4.0-7.0 mmol/L, and 92% in 4.0-7.75 mmol/L. The average feed rate was 63% of patient specific goal feed and the average insulin dose was 2.6U/hour. There was one hypoglycaemic measurement of 2.1 mmol/L. No departures from protocol or clinical interventions were required at any time. Summary: Modulating both low dose insulin boluses and nutrition input rates challenges the current practice of using only insulin in larger doses to reduce hyperglycaemic levels. Clinical results show very tight control in safe glycaemic bands. The approach could be readily adopted in any typical ICU.
Export Options
About this article
Cite this article as:
Chase Geoffrey J., Shaw M. Geoffrey, Lotz Thomas, LeCompte Aaron, Wong Jason, Lin Jessica, Lonergan Timothy, Willacy Michael and Hann E. Christopher, Model-Based Insulin and Nutrition Administration for Tight Glycaemic Control in Critical Care, Current Drug Delivery 2007; 4 (4) . https://dx.doi.org/10.2174/156720107782151223
DOI https://dx.doi.org/10.2174/156720107782151223 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Progress of Oral Insulin and Related Drug Delivery Systems and their Pharmacokinetics
Current Drug Metabolism Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews Role of Monocarboxylate Transporters in Drug Delivery to the Brain
Current Pharmaceutical Design Growing Burden of Diabetes in Sub- Saharan Africa: Contribution of Pesticides ?
Current Diabetes Reviews Epidemiology of Type 1 Diabetes in Latin America
Current Diabetes Reviews Bacteriophage - A Common Divergent Therapeutic Approach for Alzheimer's Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Structure Activity Relationship Studies of Gymnemic Acid Analogues for Antidiabetic Activity Targeting PPARγ
Current Computer-Aided Drug Design Anti-HCV Prevalence among Diabetic and Non-Diabetic Egyptian Children
Current Diabetes Reviews Clozapine Safety, 40 Years Later
Current Drug Safety Pharmacology and Chemistry of Diabetes mellitus and Antidiabetic Drugs: A Critical Review
Current Medicinal Chemistry Evolving Insights into the Pathophysiology of Diabetic Neuropathy: Implications of Malfunctioning Glia and Discovery of Novel Therapeutic Targets
Current Pharmaceutical Design Changes in Serum Nampt Levels and Its Significances in Diabetic Nephropathy Patients-The Potential Role of Nampt in T2DM with Diabetic Nephropathy
Endocrine, Metabolic & Immune Disorders - Drug Targets The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions
Current Diabetes Reviews Erythropoietin and Oxidative Stress
Current Neurovascular Research Insulin Therapy: Going The "Smarter" Way
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Complex Inter-Relationship Between Diabetes and Schizophrenia
Current Diabetes Reviews More Effective DPP4 Inhibitors as Antidiabetics Based on Sitagliptin Applied QSAR and Clinical Methods
Current Computer-Aided Drug Design GHB in Biological Specimens: Which Cut-off Levels Should be Taken into Consideration in Forensic Toxicological Investigation?
Recent Patents on Biotechnology Structure-Function Relationships and Clinical Applications of L-Asparaginases
Current Medicinal Chemistry Pills of Emergency Medicine: Deal or Not Deal?
Reviews on Recent Clinical Trials